Companies Dominating the Pulmonary Fibrosis Treatment Landscape
- Boehringer Ingelheim GmbH
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- F. Hoffmann-La Roche Ltd.
- FibroGen, Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- MediciNova, Inc.
- Genentech, Inc.
- Cipla Inc.
- Biogen
- Galapagos NV
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of pulmonary fibrosis treatment is estimated at USD 3.42 billion.
Pulmonary Fibrosis Treatment Market size was over USD 3.25 billion in 2024 and is anticipated to cross USD 7.1 billion by 2037, growing at more than 6.2% CAGR during the forecast period i.e., between 2025-2037.
Asia Pacific industry is predicted to dominate majority revenue share by 2037, driven by growing presence of leading companies involved in research and development activities for the manufacturing of effective drugs.
The major players in the market are Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., FibroGen, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, MediciNova, Inc., Genentech, Inc., Cipla Inc., Biogen and Galapagos NV.
